MNM Rosa Nogues

M Rosa Nogues

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M Rosa Nogues has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Paper in Health Sciences: The Student Mentor

    by Marta Romeu, Núria Taltavull, Carlota M Moragas, Rosa M Valls, Mireia Ribé, Lucía Tarro, Jordi Farré, M Luisa Albina, M del Carme Casajuana, Victoria Arija, et al.

  • Efecto agudo y subagudo de la carboximaltosa férrica sobre la inflamación y moléculas de adhesión en pacientes con insuficiencia renal crónica prediálisis

    by Merche Prats, Ramon L Font, Carmen Garciaruiz, C Cabre, Monica Munozcortes, M Rosa Nogues, M Jariod, Marta Romeu, A Martinezvea

    Treatment with parenteral iron causes oxidative stress, inflammation and endothelial dysfunction. Ferric carboxymaltose (FCM) is a new preparation of non-dextran iron which, due to its pharmacokinetics and stability, may induce less toxicity than other iron molecules. The aim of this study was to analyse the effect of FCM on inflammation and adhesion molecules in chronic kidney disease (CKD). Forty-seven patients with predialysis CKD and iron-deficiency anaemia received a single dose of FCM (15 mg/kg, maximum dose 1 gram). At baseline and after 60 minutes (acute effect) and after 3 weeks and 3 months (sub-acute effect), we determined inflammatory markers: C-reactive protein (CRP), interleukin-6 (IL-6) and endothelial dysfunction: intercellular adhesion molecule (ICAM) and vascular adhesion molecule (VCAM). Treatment with FCM was associated with a significant increase in haemoglobin levels: 10 (0.7) vs. 11.4 (1.3)g/dl, p<.0001. CRP, IL-6, ICAM and VCAM levels did not correlate with baseline haemoglobin or ferritin levels and there was no relationship between changes in these markers and those of haemoglobin after administration of FCM. No significant, acute or sub-acute changes occurred in any of the inflammatory or endothelial markers studied. Statin therapy was associated with lower VCAM concentrations. Treatment with high doses of FCM in patients with predialysis CKD has no proinflammatory effect and does not alter levels of adhesion molecules ICAM and VCAM in this population.


  • Open Access

    Oxidative Stress in Patients With Early Stage Chronic Lymphocytic Leukemia, Assessment and Correlation With Prognostic Factors

    by Ortín, Xavier Ortín, Montserrat Giralt, Marta Romeu, Marylene Lejeune, M Rosa Nogues, Vanessa Sanchez-Martos, Marta Rodriguez-Luaces, Teresa Sans, Llorenç Font

    Background: The heterogeneous clinical outcome that characterizes chronic lymphocytic leukemia (CLL) can be predicted by a serie of clinical prognosis factors. However, the existence of a significant subset of patients with early stage CLL makes crucial the need of more accurate prognostic markers allowing the possibility of early treatment of these patients. Although high reactive oxygen species (ROS) levels have been seen to play a role in CLL, discrepancies in the information compiled about oxidative stress (OS) in these patients have been reported. Methods: In this study, we evaluate the overall OS status, through a recently defined score of oxidative stress (SOS), of 37 early stage CLL patients and we compare SOS with well-known prognosis factors and with a matched control group of healthy individuals. Results: We have observed an imbalance in the antioxidant/prooxidant equilibrium in early stage CLL patients with a significant higher SOS than that of the healthy control group (0.00 ± 0.53 vs. 2.97 ± 1.13; P < 0.05). Most of the patients who exhibit 3 - 4 adverse prognosis factors also present higher values of most of the OS biomarkers and SOS. Conclusions: These data strongly suggest that the combination strategy of OS biomarkers with already known prognosis factor may have potential clinical applications in early stage CLL patients. doi: http://dx.doi.org/10.4021/jh34w


  • Melatonin reduces oxidative stress in erythrocytes and plasma of senescence‐accelerated mice

    by M. Rosa Nogués, Montserrat Giralt, Marta Romeu, Miquel Mulero, Vanesa Sánchez‐Martos, Esperanza Rodríguez, Darío Acuña‐Castroviejo, Jordi Mallol

    Abstract:  It has been suggested that oxidative stress is a feature of aging. The goal of the present study was to assess the oxidant effects related to aging and the protective role of exogenous melatonin in senescence‐accelerated mice (SAMP8). Two groups of SAMP8 mice (males and females) were compared with their respective control groups of SAMR1 mice (senescence‐resistant inbred strain) to determine their oxidative status without melatonin treatment. Four other groups of the same characteristics were treated with melatonin (10 mg/kg/day) in their drinking water. The melatonin concentration in the feeding bottles was titrated according to water consumption and body weight (i.e. 0.06 mg/mL for 30 g of body weight and 5 mL/day of water consumption). The treatment began when animals were 1‐month old and continued for 9 months. When mice were 10‐month old, they were anesthetized and blood was obtained. Plasma and erythrocytes were processed to examine oxidative stress markers: reduced glutathione (GSH), oxidized glutathione (GSSG), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), glutathione reductase (GR), glutathione S‐transferase (GST), thiobarbituric acid reactive substances (TBARS), and hemolysis. The results showed greater oxidative stress in SAMP8 than in SAMR1, largely because of a decrease in GSH levels and to an increase in GSSG and TBARS with the subsequent induction of the antioxidant enzymes GPX and GR. Melatonin, as an antioxidant molecule, improved the glutathione‐related parameters, prevented the induction of GPX in senescent groups, and promoted a decrease in SOD and TBARS in almost all the groups.